On Tuesday, Arrowhead Pharmaceuticals said it will shift focus to its experimental cardiometabolic drug plozasiran and will deprioritize its work on zodasiran, emphasizing the need …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.